683 Capital Management LLC Buys 1,065,000 Shares of InflaRx N.V. $IFRX

683 Capital Management LLC grew its holdings in InflaRx N.V. (NASDAQ:IFRX) by 47.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,315,000 shares of the company’s stock after purchasing an additional 1,065,000 shares during the quarter. 683 Capital Management LLC’s holdings in InflaRx were worth $3,348,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Squarepoint Ops LLC raised its holdings in shares of InflaRx by 72.0% in the 4th quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock valued at $328,000 after purchasing an additional 135,826 shares in the last quarter. HRT Financial LP bought a new stake in shares of InflaRx in the 4th quarter valued at about $47,000. Insigneo Advisory Services LLC bought a new stake in shares of InflaRx in the 4th quarter valued at about $61,000. T3 Companies LLC bought a new stake in shares of InflaRx in the 4th quarter valued at about $294,000. Finally, DCF Advisers LLC bought a new stake in shares of InflaRx in the 4th quarter valued at about $160,000. Institutional investors own 42.39% of the company’s stock.

Analyst Upgrades and Downgrades

IFRX has been the subject of several recent research reports. Guggenheim restated a “buy” rating and issued a $14.00 price target on shares of InflaRx in a report on Tuesday, April 21st. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. HC Wainwright lifted their price objective on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Oppenheimer assumed coverage on shares of InflaRx in a research report on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective on the stock. Finally, Cantor Fitzgerald lifted their price objective on shares of InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

InflaRx Price Performance

IFRX stock opened at $1.82 on Thursday. The firm’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $1.31. The company has a market capitalization of $131.57 million, a P/E ratio of -2.56 and a beta of 2.42. InflaRx N.V. has a 12 month low of $0.74 and a 12 month high of $2.95.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.08. As a group, sell-side analysts forecast that InflaRx N.V. will post -0.4 earnings per share for the current year.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.